GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pieris Pharmaceuticals Inc (NAS:PIRS) » Definitions » Cyclically Adjusted Book per Share

Pieris Pharmaceuticals (Pieris Pharmaceuticals) Cyclically Adjusted Book per Share : $54.40 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Pieris Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Pieris Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2024 was $17.760. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $54.40 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Pieris Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 5.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-11), Pieris Pharmaceuticals's current stock price is $10.40. Pieris Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $54.40. Pieris Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.19.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Pieris Pharmaceuticals was 1.52. The lowest was 0.19. And the median was 0.33.


Pieris Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Pieris Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pieris Pharmaceuticals Cyclically Adjusted Book per Share Chart

Pieris Pharmaceuticals Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 52.99

Pieris Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.48 52.88 52.63 52.99 54.40

Competitive Comparison of Pieris Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Pieris Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pieris Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pieris Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pieris Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Pieris Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pieris Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=17.76/131.7762*131.7762
=17.760

Current CPI (Mar. 2024) = 131.7762.

Pieris Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.058 100.560 0.076
201409 -0.006 100.428 -0.008
201412 49.198 99.070 65.440
201503 38.674 99.621 51.157
201506 30.301 100.684 39.658
201509 67.710 100.392 88.878
201512 62.517 99.792 82.554
201603 54.580 100.470 71.587
201606 69.285 101.688 89.785
201609 58.491 101.861 75.669
201612 46.869 101.863 60.633
201703 33.509 102.862 42.928
201706 17.033 103.349 21.718
201709 8.213 104.136 10.393
201712 20.476 104.011 25.942
201803 75.136 105.290 94.037
201806 81.940 106.317 101.562
201809 74.255 106.507 91.873
201812 58.998 105.998 73.346
201903 49.093 107.251 60.319
201906 31.643 108.070 38.584
201909 33.433 108.329 40.669
201912 74.406 108.420 90.435
202003 72.166 108.902 87.324
202006 71.256 108.767 86.330
202009 62.449 109.815 74.938
202012 44.322 109.897 53.146
202103 51.221 111.754 60.398
202106 56.055 114.631 64.439
202109 60.251 115.734 68.602
202112 56.221 117.630 62.982
202203 57.708 121.301 62.691
202206 47.796 125.017 50.380
202209 38.456 125.227 40.467
202212 29.983 125.222 31.552
202303 16.595 127.348 17.172
202306 32.775 128.729 33.551
202309 24.691 129.860 25.055
202312 21.637 129.419 22.031
202403 17.760 131.776 17.760

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Pieris Pharmaceuticals  (NAS:PIRS) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Pieris Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=10.40/54.4
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Pieris Pharmaceuticals was 1.52. The lowest was 0.19. And the median was 0.33.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Pieris Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Pieris Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Pieris Pharmaceuticals (Pieris Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
225 Franklin Street, 26th Floor, Boston, MA, USA, 02110
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.
Executives
Ann Barbier director 255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109
Peter A Kiener director 40 GUEST STREET, BOSTON MA 02135
Maya R. Said director C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Matthew L Sherman director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Christopher P Kiritsy director
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Shane Olwill officer: Chief Development Officer C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Ahmed Mousa officer: Chief Business Officer 255 STATE STREET, 9TH FLOOR, C/O PIERIS PHARMACEUTICALS, INC., BOSTON MA 02109
Hitto Kaufmann officer: Chief Scientific Officer C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Thomas Bures officer: Chief Financial Officer C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Tim Demuth officer: Chief Medical Officer C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Aquilo Capital Management, Llc 10 percent owner ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104